※ PTMD 2.0 database Online Browse Options

Browse result for Heart failure

※ introduction

    Heart failure (HF), also known as congestive heart failure (CHF), is a syndrome caused by an impairment in the heart's ability to fill with and pump blood. Although symptoms vary based on which side of the heart is affected, HF typically presents with shortness of breath, excessive fatigue, and bilateral leg swelling. The severity of the heart failure is mainly decided based on ejection fraction and also measured by the severity of symptoms. Other conditions that have symptoms similar to heart failure include obesity, kidney failure, liver disease, anemia, and thyroid disease. Common causes of heart failure include coronary artery disease, heart attack, high blood pressure, atrial fibrillation, valvular heart disease, excessive alcohol consumption, infection, and cardiomyopathy. These cause heart failure by altering the structure or the function of the heart or in some cases both. There are different types of heart failure: right-sided heart failure, which affects the right heart, left-sided heart failure, which affects the left heart, and biventricular heart failure, which affects both sides of the heart. Left-sided heart failure may be present with a reduced ejection fraction or with a preserved ejection fraction. Heart failure is not the same as cardiac arrest, in which blood flow stops completely due to the failure of the heart to pump. Diagnosis is based on symptoms, physical findings, and echocardiography. Blood tests, and a chest x-ray may be useful to determine the underlying cause. Treatment depends on severity and case. For people with chronic, stable, mild heart failure, treatment usually consists of lifestyle changes, such as not smoking, physical exercise, and dietary changes, as well as medications. In heart failure due to left ventricular dysfunction, angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin inhibitors, along with beta blockers, mineralocorticoid receptor antagonists and SGLT2 inhibitors are recommended. Diuretics may also be prescribed to prevent fluid retention and the resulting shortness of breath. Depending on the case, an implanted device such as a pacemaker or implantable cardiac defibrillator may sometimes be recommended. In some moderate or more severe cases, cardiac resynchronization therapy (CRT) or cardiac contractility modulation may be beneficial. In severe disease that persists despite all other measures, a cardiac assist device ventricular assist device, or, occasionally, heart transplantation may be recommended. Heart failure is a common, costly, and potentially fatal condition, and is the leading cause of hospitalization and readmission in older adults. Heart failure often leads to more drastic health impairments than failure of other, similarly complex organs such as the kidneys or liver. In 2015, it affected about 40 million people worldwide. Overall, heart failure affects about 2% of adults, and more than 10% of those over the age of 70. Rates are predicted to increase. The risk of death in the first year after diagnosis is about 35%, while the risk of death in the second year is less than 10% in those still alive. The risk of death is comparable to that of some cancers. In the United Kingdom, the disease is the reason for 5% of emergency hospital admissions. Heart failure has been known since ancient times; it is mentioned in the Ebers Papyrus around 1550 BCE.

Reference
Wiki: Heart failure



PTMD IDUniProt AccessionEntrez IDGene NameProtein NameOrganism
PTMD00519P095431267
CNP
2',3'-cyclic-nucleotide 3'-phosphodiesterase
Homo sapiens
PTMD00574P299664082
MARCKS
Myristoylated alanine-rich C-kinase substrate
Homo sapiens
PTMD00086P630005879
RAC1
Ras-related C3 botulinum toxin substrate 1
Homo sapiens
PTMD00376P263581786
DNMT1
DNA -methyltransferase 1
Homo sapiens
PTMD00450O0042910059
DNM1L
Dynamin-1-like protein
Homo sapiens
PTMD00466O435838562
DENR
Density-regulated protein
Homo sapiens
PTMD00155P16615488
ATP2A2
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 -ATPase 2) ATPase)
Homo sapiens
PTMD00935Q9NPH550507
NOX4
NADPH oxidase 4 H-oxidase)
Homo sapiens
PTMD00660Q061245781
PTPN11
Tyrosine-protein phosphatase non-receptor type 11
Homo sapiens
PTMD00552P194297137
TNNI3
Troponin I, cardiac muscle
Homo sapiens
PTMD01934Q9UQL610014
HDAC5
Histone deacetylase 5
Homo sapiens
PTMD01162Q927366262
RYR2
Ryanodine receptor 2
Homo sapiens
PTMD01057P057833875
KRT18
Keratin, type I cytoskeletal 18
Homo sapiens
PTMD01627P453797139
TNNT2
Troponin T, cardiac muscle
Homo sapiens
PTMD01733Q128093757
KCNH2
Potassium voltage-gated channel subfamily H member 2
Homo sapiens
PTMD01131Q148964607
MYBPC3
Myosin-binding protein C, cardiac-type
Homo sapiens
PTMD01878Q9BR3957158
JPH2
Junctophilin-2 [Cleaved into: Junctophilin-2 N-terminal fragment ]
Homo sapiens
PTMD00206Q7TQN430916
Rela
Nuclear factor kappaB subunit p65 )
Rattus norvegicus
PTMD00920Q0PCR612288
Cacna1c
Voltage-dependent L-type calcium channel subunit alpha
Mus musculus
PTMD00108Q0836914463
Gata4
Transcription factor GATA-4
Mus musculus
PTMD01400E9Q40120191
Ryr2
Ryanodine receptor 2
Mus musculus
PTMD01490P0805024392
Gja1
Gap junction alpha-1 protein
Rattus norvegicus
PTMD01569P2754617758
Map4
Microtubule-associated protein 4
Mus musculus
PTMD01628P4615254254
Gata4
Transcription factor GATA-4
Rattus norvegicus
PTMD01652P5166717906
Myl2
Myosin regulatory light chain 2, ventricular/cardiac muscle isoform
Mus musculus
PTMD01344P6308526413
Mapk1
Mitogen-activated protein kinase 1
Mus musculus
PTMD01697P7028815182
Hdac2
Histone deacetylase 2
Mus musculus
PTMD01715Q0114712912
Creb1
Cyclic AMP-responsive element-binding protein 1
Mus musculus
PTMD01786Q5EG4710578
Prkaa1
5'-AMP-activated protein kinase catalytic subunit alpha-1
Mus musculus